Opinion & analysis | Page 20 of 20 | Report Store

Pharma Intelligence Report Store Article Collection Innovation, Data and Machine Learning Report 1

Real-world evidence promises to solve many problems inherent in getting a drug to patients at a good price. It could slash development costs and help make the reimbursement case to payers. But there are challenges for companies that want to exploit real-world evidence to get their drug to patients in Europe.

November 22, 2016

Find out more

Pharma Intelligence Report Store Article Collection Innovation, Data and Machine Learning Report 2

$500.00

OTC drug firms should offer more digital tools that guide consumers in product purchases, says a health care marketing executive. The American Pharmacists Association suggests firms also strengthen outreach with pharmacists.

March 16, 2017

Find out more

Mail Order and Internet Pharmacy in Europe

$740.00

This 17-country study finds that continued growth of mobile technologies and e-commerce,combined with a more stable regulatory environment, are driving changes in the European mail order and Internet pharmacy market.

January 18, 2017

Find out more

OTC Distribution in Europe – The New Global Agenda

$2,845.00

This comprehensive study identifies key factors driving change in the channels through which non-prescription/OTC medicines are distributed in Europe (18 main EU markets, plus Norway and Switzerland) and highlights the challenges facing suppliers in an ever-changing market.

January 18, 2016

Find out more

Wearables are Transforming R&D and Care Delivery

$2,995.00

Wearable technologies have the potential to transform medicine and the delivery of healthcare more significantly than any other component of the digital revolution – or indeed than many other scientific advances.

June 6, 2016

Find out more

Data in Healthcare: Underpinning the Shift to Value

$2,995.00

Data plays a key role in healthcare systems’ shifts towards value-focused outcomes. Such data includes outcomes and cost data, adherence data, and increasingly, patient-reported data, behavioral and social media data.

November 23, 2016

Find out more

Transforming Pharmaceutical R&D with Data

$2,995.00

Ongoing pressures on drug pricing and reimbursement mean that current research and development (R&D) economics are unsustainable. The process of discovering and developing a drug has not fundamentally changed for decades, and on average it still costs $2.6bn and takes over 10 years. Fortunately, tools are emerging to help improve R&D success rates. Most are built on better use of more kinds of data, including using artificial intelligence (AI) to process massive quantities of information that humans cannot manage. Some of these new tools promise cost and time savings of between 20–50%

May 2, 2017

Find out more

The Intersection Between Tech and Pharma Special Report (Part 2. Apple)

$3,000.00

In January 2015, Fortune reported that at $2.9tn, the state of the US healthcare industry is very strong and continues to grow. Additionally, a Top Issues report revealed that 40% of Fortune 50 companies pursued new healthcare partnerships in 2014. Given the rapid change in the healthcare industry over the last few years, it is no surprise that we are starting to see more non-traditional healthcare partnerships, specifically with big tech companies.

January 14, 2016

Find out more

The Intersection Between Tech and Pharma Special Report (Part 3. Intel, Samsung, IBM, and GE)

$3,000.00

The Intersection Between Tech and Pharma Special Report (Part 3. Intel, Samsung, IBM, and GE)

January 22, 2016

Find out more

Special Report: The Intersection Between Tech and Pharma (Part 1. Google)

$3,000.00

In January 2015, Fortune reported that at $2.9tn, the state of the US healthcare industry is very strong and continues to grow.

January 2, 2016

Find out more

2021 J.P. Morgan Healthcare Conference Review

$4,750.00

The 39th annual J.P. Morgan Healthcare Conference (JPM) was held virtually from January 11-14, 2021. A list of events and catalysts that were announced or updated at the conference are included in this report. Below are some key points from company presentations.

January 25, 2021

Find out more

Interventional Cardiology: Implantable Cardioverter Defibrillators

$4,750.00

The ICD market alone lost nearly $1bn from $8.3bn in 2019 to $7.4bn in 2020 due to a combination of lockdowns, supply chain disruptions, and logistical strain in the healthcare space. The global market for ICD devices, along with many other medical devices, is currently recovering from a major economic downturn. Therefore, to provide context as to the nature of this market recovery and what exactly it is recovering from, data from 2019 are included. Types of cardiac defibrillators covered by the scope of this report include ICDs, subcutaneous ICDs (S-ICDs), and cardiac resynchronization therapy defibrillators (CRT-Ds). The regions covered by this report are the US, the 5 major European economies (UK, France, Spain, Italy, Germany), Japan, and the rest of the world. The forecast range is 2020-2025.

December 21, 2021

Find out more

Interventional Neurology: Cerebral Aneurysm and Arteriovenous Malformation Systems

$4,750.00

This medical market and technology report provides a comprehensive discussion of the global market for neurointerventional cerebral aneurysm and AVM embolization systems. This market comprises the following product segments: endovascular coils, liquid embolics, stents for stent-assisted coiling, flow diversion and flow disruption systems, and other novel/emerging embolization devices. Markets covered by this analysis comprise the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the rest of world (RoW) markets. The forecast range for this report is 2020–25.

December 21, 2021

Find out more

Digital Health Technology and Regulatory Overview

$4,750.00

This technology report provides an overview of the current landscape for digital health devices and software. This includes a summary of regulation and reimbursement policies and highlights of major product categories.

December 13, 2021

Find out more